Pain is an unpleasant sensory and emotional experience, often associated with actual or potential tissue damage, that serves as a warning signal to the body, prompting protective actions.
Anxiety is characterized by intense fear, worry, and unease, while depression is a prolonged state of low mood, loss of interest, and difficulty functioning.
Cannabidiol (CBD) is a primary component in the cannabis plant; however, in recent years, interest in CBD treatments has outpaced scientific research and regulatory advancement resulting in a confusing landscape of misinformation and unsubstantiated health claims.
Within the limited results from randomized controlled trials, and lack of trust in product quality and known clinical guidelines and dosages, real-world evidence (RWE) from countries with robust regulatory frameworks may fill a critical need for patients and healthcare professionals.
Despite growing evidence and interest, no real-world data (RWD) studies have yet investigated patients’ reports of CBD impact on symptom control in the common expression of pain, anxiety, depression, and poor wellbeing.
The objective of this study is to assess the impact of CBD-rich treatment on symptom burden, as measured with a specific symptom assessment scale (ESAS-r)
This retrospective observational study examined pain, anxiety, depression symptoms, and wellbeing in 279 participants over 18 years old, prescribed with CBD-rich treatment at a network of clinics dedicated to medical cannabis in Quebec, Canada.
Data were collected at baseline, 3 (FUP1), and 6 (FUP2) month after treatment initiation.
Groups were formed based on symptom severity (mild vs moderate/severe) and based on changes to treatment plan at FUP1 (CBD vs THC:CBD).
Two-way mixed ANOVAs were used to assess ESAS-r scores differences between groups and between visits.
All average ESAS-r scores decreased between baseline and FUP1 (all ps < 0.003).
The addition of delta-9-tetrahydrocannabinol (THC) during the first follow-up had no effect on symptom changes.
Patients with moderate/severe symptoms experienced important improvement at FUP1 (all ps < 0.001), whereas scores on pain, anxiety, and wellbeing of those with mild symptoms actually increased.
Differences in ESAS-r scores between FUP1 and FUP2 were not statistically different.
This retrospective observational study suggests CBD-rich treatment has a beneficial impact on pain, anxiety, and depression symptoms as well as overall wellbeing only for patients with moderate to severe symptoms; however, no observed effect on mild symptoms.
The results of this study contribute to address the myths and misinformation about CBD treatment and demand further investigation.
Reference:
Rapin L, Gamaoun R, El Hage C, Arboleda MF, Prosk E. Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic. J Cannabis Res. 2021 Jun 23;3(1):19. doi: 10.1186/s42238-021-00078-w. PMID: 34162446; PMCID: PMC8223341.
Image Courtesy of Sante Cannabis
Courtesy of the National Library of Medicine
Check out our FAQ
© CBD Oil Community 2025. We recommend consulting with a qualified medical professional before starting any new supplement especially if you have health conditions or take medication. Your health is a priority and expert guidance can help you make informed decisions. All information on this website is for informational purposes only and should not be considered medical advice. The use of medicinal cannabis is regulated by State and Territory legislation and individuals should consult their healthcare practitioner about treatment options. CBD Oil Community accepts no responsibility or liability for reliance on the information provided here.
